Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Gene-modified (GM) T cell therapy
Gene-modified T cell therapy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants exposed to Gene-modified (GM) T cell therapy | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Gene-modified (GM) T cell therapy | GENETIC | No investigational product will be administered |
Inclusion Criteria: * Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment pr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Gene-modified T cell therapy is an investigational gene therapy being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Gene-modified T cell therapy is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
Gene-modified T cell therapy is currently in Phase 2 clinical development. It is an investigational therapy, meaning it has not yet been approved by regulatory agencies such as the FDA. The therapy is being studied in an ongoing clinical trial to assess its long-term effects in patients.
Gene-modified T cell therapy is being evaluated in a single clinical trial registered as NCT03435796. This Phase 2 study, titled 'Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells,' is currently recruiting participants with neoplasms across multiple countries, including the United States, Australia, and several European and Asian nations.
Yes, Gene-modified T cell therapy is also known as Gene-modified (GM) T cell therapy. These names refer to the same investigational therapy being developed by Bristol-Myers Squibb. The therapy involves modifying a patient's T cells to target and potentially treat neoplasms.